NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 12th March 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items
2. Dr James Fotheringham (Vice-chair) Present for all items
3. Alan Thomas Present for all items
4. Becky Pennington Present for all items
5. Dominic Pivonka Present for all items
6. Dr Andrew Champion Present for all items
7. Dr Ian Bernstein Present for all items
8. Dr Justin Daniels Present for all items
9. Dr Mohit Sharma Present for all items
10. Dr Peter Baker-Gulliver Present for all items
11. Dr Steve Edwards Present for all items
12. Hugo Pedder Present for all items
13. Jaqueline Tomlinson Present for all items
14. Mario Ganau Present for all items
15. Min Ven Teo Present for all items
16. Mohamad Farhat Present for all items
17. Patrick de Barr Present for all items
18. Professor G.J. Melendez-Torres Present for all items
19. Richard Ballerand Present for all items

NICE staff (key players) present

Jacoline Bouvy, Programme Director Present for all items

Janet Robertson, Associate Director Present for all items

Thomas Fiest, Project Manager Present for all items

Sally Doss, Heath Technology Assessment Adviser Present for all items

Thomas Palmer, Heath Technology Assessment Analyst Present for all items

External assessment group representatives present

Dan Pollard, School of Health and Related Research Items 1.1 to 4.1.3

Clinical, Patient & NHS England experts present

John-Paul Kilday, Paediatric Neuro-oncology Consultant, Clinical expert, nominated by Novartis Items 1.1 to 4.1.3

Lynley Marshall, Consultant in Paediatric and Adolescent Oncology Drug Development, Clinical expert, nominated by Novartis Items 1.1 to 4.1.3

Sukhdip Sandhu, Patient expert, nominated by The Brain Tumour Charity

 Items 1.1 to 4.1.3

Clare Jackson, Frontline Support Manager, Patient expert, nominated by The Brain Tumour Charity Items 1.1 to 4.1.3

Peter Clark, NHSE CDF clinical lead Present for all items

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Craig Buckley, Pratheeban Nambyiah, Ravi Ramessur and Ana Duarte.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 13th February 2024

### Appraisal of [Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 to 17 [ID5104]](https://www.nice.org.uk/guidance/indevelopment/gid-ta11006)

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Novartis.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11006).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Mohamad Farhat (clinical), Dominic Pivonka (cost) and Alan Thomas (lay).
	2. Part 2 – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached through a vote by members.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11006>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 9th April and will start promptly at 9:00am.